In addition, consideration should be given to side effects of the implementation of malaria chemoprophylaxis, e.g., although there is a low prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency in ROK populations, hemolytic anemia, a potentially fatal adverse event, may occur in patients who are G6PD-deficient, when administered primaquine to treat the liver stage parasites to prevent the recurrence of vivax malaria [20]. This evidence concerns the gene G6PD and G6PD deficiency.